Amarin Co. ADR Logo
US0231112063
A0NBNG
AMRN

Amarin Co. ADR

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 1,98 € (-80,68 %). La mediana es de 1,82 € (-82,24 %).

Comprar
  3
Mantener
  13
Vender
  2

Debates en la comunidad

  • Ticker Symbol neben ISIN und WKN

    OM Olaf Müller IV en Portfolio Tracking

    3 2

  • Amarin reports 42% revenue decline after missing prior-year license payment

    Amarin reported a 42% decline in net revenues for Q2, mainly due to the absence of a $25m license prepayment from Recordati in the prior-year period. Operating expenses fell 59% to $27m after completing a $70m cost‑reduction initiative. US sales of VASCEPA decreased slightly because of generic competition and net price pressure, partly offset by demand; the company recorded its third consecutive quarter of positive cash flow and expects international growth, stable US sales volumes, positive cash flow and a 10% increase in liquid funds by the end of 2026. » Más en de.investing.com


  • Amarin emphasizes cost advantage of VASCEPA after approval of new injectable therapies

    Amarin clarifies that VASCEPA remains a treatment option for severe hypertriglyceridemia and reduced triglycerides by a median of 33% versus placebo. About 50% of patients reached levels below 500 mg/dL after 12 weeks. The company highlights that the annual wholesale prices of the new injectable APOC3 therapies are around $40,000, while VASCEPA costs about $4,200 per patient. Amarin also points to over 30 million prescriptions and the cardiovascular approval in combination with statins. » Más en de.investing.com


  • Amarin shareholders block share issuances and restrict equity compensation

    Amarin shareholders rejected several key proposals, including the renewal of the authorization to issue new shares, an increase in the reserve under the 2020 Stock Incentive Plan, and the issuance of shares without UK pre-emption rights. While the re-election of several board members and the advisory approval of executive pay were passed, they received lower support levels. The board warns this will severely limit the grant of equity-based incentives, make future variable pay primarily cash‑based, and incur additional costs for paper shareholder communications. Shareholders approved the appointment of Ernst & Young as auditor for fiscal year 2026. » Más en de.investing.com


  • Amarin increases sales and reduces operating loss through restructuring

    Amarin reported a 7.4% increase in total net revenue for Q1 2026 to $45.1 million and, thanks to restructuring measures, cut operating expenses by 31%. The operating loss fell 32.7% to $11.3 million. The company generated positive cash flow for the second consecutive quarter ($6.4 million) and held $308 million in cash at quarter-end. Vascepa prescriptions in the US rose 17%, and the partnership with Recordati contributed to strong revenue growth in Europe. Amarin expects positive full-year cash flow for 2026 and forecasts Q2 EPS of $0.54, but notes risks from generic competition and regulatory hurdles. » Más en de.investing.com


  • Amarin to release quarterly results on Feb. 25, 2026

    Amarin will release results for the quarter ended Dec. 31, 2025 on Feb. 25, 2026. Three analysts see an average EPS of $0.034 per share, after a loss of -$2.380 in the year-ago quarter. The consensus expects quarterly revenue of $54.6 million (‑11.6% vs. $61.7 million a year earlier). For the fiscal year, three analysts on average forecast a loss of -$0.661 per share and revenue of $222.5 million compared with $228.7 million the prior year. » Más en finanzen.net

En 2012, Amarin Co. ADR ya ha pagado 0,0939 € en dividendos. El último pago fue en octubre de 2012.

Datos financieros de la empresa

En el último trimestre, Amarin Co. ADR tuvo unos ingresos de 34,92 M € y un beneficio neto de 216,3 mil €
(EUR) septiembre de 2026
YoY
Ingresos 34,92 M 17,50 %
Beneficio bruto 14,29 M 24,51 %
Beneficio neto 216,3 mil 103,28 %
EBITDA 842,24 mil 219,08 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
213,04 M €
Número de acciones
20,68 M
Máximo/mínimo de 52 semanas
15,76 € - 10,25 €
Dividendos No
Beta
0,79
Ratio P/E
-10,80
Ratio PEG
-0,07
Ratio P/B
0,53
Ratio P/S
1,33

Perfil de la empresa

Amarin Corporation plc, una empresa farmacéutica, se dedica al desarrollo y la comercialización de terapias para el tratamiento de enfermedades cardiovasculares en Estados Unidos, Alemania, Canadá, Líbano y los Emiratos Árabes Unidos. Su producto principal es VASCEPA, un producto de ácidos grasos omega-3 de venta exclusiva con receta, utilizado como complemento a la dieta para reducir los niveles de triglicéridos en pacientes adultos con hipertrigliceridemia grave. La empresa vende sus productos principalmente a mayoristas y proveedores de farmacias especializadas. Mantiene una colaboración con Mochida Pharmaceutical Co., Ltd. para desarrollar y comercializar productos farmacéuticos e indicaciones basados en el principio farmacéutico activo de Vascepa, el ácido omega-3, y el ácido eicosapentaenoico. La empresa era conocida anteriormente como Ethical Holdings plc y cambió su nombre a Amarin Corporation plc en 1999. Amarin Corporation plc se constituyó en 1989 y tiene su sede central en Dublín, Irlanda.

Nombre
Amarin Co. ADR
CEO
Aaron D. Berg
Sede Dublin, du
Irlanda
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
01/04/1993
Empleados 80

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
AMRN
Frankfurt
EH3A.F
Düsseldorf
EH3A.DU
München
EH3A.MU
🍪

Parqet  usa cookies. Más información